Corvus Pharmaceuticals announced a conference call and webcast on November 5, 2026, to provide a business update and report its third quarter 2026 financial results. The company is a clinical-stage biopharmaceutical firm developing soquelitinib, a drug in trials for cancer and immune diseases. Investors can access the event via phone or webcast, with a replay available for 90 days. This update is important as it may reveal progress in their clinical trials and financial health.
Corvus Pharmaceuticals' upcoming business update and Q3 2026 results provide context for health-sector trading. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced health-sector US stocks, 95 rose and 47 fell. Vertex Pharmaceuticals (VRTX) traded at USD 547.98 with a 3.45% gain and a typical hold time of 122 days, contrasting with Inovio Pharmaceuticals (INO) at USD 0.96, up 3.38% but held only 43 days on average. Novartis AG (NVS) stood at USD 160.96, up 3.13%, with a hold time of 84 days, showing a range of investor engagement across these health stocks.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
